Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pars Plana Vitrectomy With Internal Limiting Membrane Peeling Versus Intravitreal Ziv-Aflibercept for Treatment-Naïve Diabetic Macular Edema

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03660345
Recruitment Status : Recruiting
First Posted : September 6, 2018
Last Update Posted : March 28, 2019
Sponsor:
Collaborators:
Ryan Rush, MD
Pedro Gomez, MD
Javier Castillo, MD
Information provided by (Responsible Party):
Sloan W. Rush, MD, Rush Eye Associates

Brief Summary:
Treatment-naïve subjects with center-involved diabetic macular edema undergoing pars plana vitrectomy with internal limiting membrane peeling will have similar visual outcomes but better anatomical outcomes compared to subjects undergoing intravitreal bevacizumab monotherapy at one year.

Condition or disease Intervention/treatment Phase
Diabetic Retinopathy Macular Edema Procedure: PPV/MP Drug: Intravitreal injection Phase 3

Detailed Description:

Diabetic retinopathy is the number one cause of vision loss in working-age adults, and macular edema is the most frequent cause of visual impairment in diabetic patients. Diabetic macular edema (DME) has been treated by a number of different modalities including focal and grid laser, intravitreal corticosteroids, intravitreal anti-vascular endothelial growth factor (VEGF) medications, and pars plana vitrectomy (PPV) with or without internal limiting membrane peeling.

PPV for the treatment of DME was first described in 1992 by Lewis et al, and since then has been studied by numerous investigators under a variety of different clinical settings including the presence of epiretinal membranes, vitreomacular traction (VMT), and diffuse DME. The postulated mechanisms by which PPV may improve DME have included a reduction in macular tangential and anterior-posterior traction, improved oxygenation of the vitreous cavity, and enhanced diffusion of vasogenic growth factors. Other factors that may modulate the response to PPV comprise the patient's lens status and the presence of macular ischemia.

PPV for DME has usually been considered only in patients that responded poorly to other interventions such as laser and/or intravitreal therapy. Typically, such patients have chronic and diffuse DME with, or without, concomitant VMT. Several small prospective, controlled trials have been performed to assess the merits of PPV as a treatment option for such recalcitrant cases with generally disappointing functional outcomes despite having structural improvements. However, since PPV was reserved as a last-ditch effort following a long ordeal with what included multiple lasers and/or intravitreal injections, it should not be surprising that visual outcomes were poor under such circumstances. Presumably most of these patients already would have had irreversible damage to the retina with little or no potential for visual acuity improvement no matter what the intervention might have been. Currently, there are no reports in the literature evaluating PPV as an initial treatment for DME. In this study, we compare PPV to anti-VEGF monotherapy in treatment-naïve subjects with DME in order to evaluate the potential role of PPV in the management of DME before irreversible retinal damage caused by long-standing and persistent DME has set in.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Pars Plana Vitrectomy With Internal Limiting Membrane Peeling Versus Intravitreal Ziv-Aflibercept for Treatment-Naïve Diabetic Macular Edema
Actual Study Start Date : September 4, 2018
Estimated Primary Completion Date : September 4, 2020
Estimated Study Completion Date : September 4, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema

Arm Intervention/treatment
Experimental: PPV/MP
Study Group: Treatment-naïve subjects with center-involved diabetic macular edema undergo pars plana vitrectomy with internal limiting membrane peeling
Procedure: PPV/MP
23 gauge Pars Plana Vitrectomy with Internal Limiting Membrane Peeling

Active Comparator: Intravitreal Injection
Control Group: Treatment-naïve subjects with center-involved diabetic macular edema undergo intravitreal ziv-aflibercept monotherapy according to a fixed treatment schedule
Drug: Intravitreal injection
Intravitreal ziv-Aflibercept




Primary Outcome Measures :
  1. BCVA [ Time Frame: 6 months ]
    Best-corrected visual acuity



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Patient able and willing to provide informed consent
  3. Diagnosis of diabetes mellitus (type 1 or type 2) is established.
  4. Patient has non-proliferative diabetic retinopathy and is treatment-naïve for diabetic retinopathy in the study eye. (Patients may NOT have received treatment of any kind for diabetic retinopathy to the study eye).
  5. Best corrected visual acuity letter score is 20/32 or worse, and 20/400 or better at the time of randomization in the study eye.
  6. On clinical exam, definite retinal thickening due to diabetic macular edema involving the center of the macula is present in the study eye.
  7. Central subfield thickness on the spectral domain OCT is greater than 300 microns at the time of randomization in the study eye.

    (The investigator must verify accuracy of OCT scan by ensuring it is centered and of adequate quality).

  8. The study eye has no history of intraocular surgery within the previous four months. Previous uncomplicated cataract surgery otherwise shall be allowed if the study eye is longer than four months out at the time of randomization.

Exclusion Criteria:

  1. Proliferative diabetic retinopathy of any kind including neovascularization of the disc/retina/iris, presence of any degree of vitreous hemorrhage, and tractional retinal detachment must be excluded.
  2. Patients that received treatment to the posterior segment for any retinal condition must be excluded. Such treatments include intravitreal injections of any kind, retinal lasers of any kind, and subtenons injections.
  3. The study eye has a history of previous anterior or pars plana vitrectomy for any reason must be excluded.
  4. The patient has a history of systemic anti-VEGF therapy or systemic corticosteroid therapy within the previous 12 months.
  5. The patient's macular edema is considered to be due to a cause other than diabetic macular edema.
  6. An ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, a nonretinal condition like corneal scarring or advanced optic nerve cupping from glaucoma, etc.).
  7. Substantial cataract that, in the opinion of the investigator, is likely decreasing visual acuity by three or more lines on its own merit (apart from the macular edema).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03660345


Contacts
Layout table for location contacts
Contact: Sunday Fowler 806-353-0125 sunday.fowler@paneye.com

Locations
Layout table for location information
Mexico
Hospital La Carlota Recruiting
Montemorelos, Nuevo Leon, Mexico
Contact: Gomez Pedro, MD         
Sponsors and Collaborators
Rush Eye Associates
Ryan Rush, MD
Pedro Gomez, MD
Javier Castillo, MD

Layout table for additonal information
Responsible Party: Sloan W. Rush, MD, Physician, Rush Eye Associates
ClinicalTrials.gov Identifier: NCT03660345     History of Changes
Other Study ID Numbers: Retina 1
First Posted: September 6, 2018    Key Record Dates
Last Update Posted: March 28, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Edema
Macular Edema
Diabetic Retinopathy
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Temazepam
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action